

# Contents

---

<i>Preface</i> .....	<i>v</i>
<i>Contributors</i> .....	<i>ix</i>
<b>I INTRODUCTION</b>	
1 Cardiac Drug Development: <i>From Animal Models to Clinical Trials</i> <i>Michael K. Pugsley</i> .....	3
<b>II NOVEL MOLECULAR TARGETS FOR CARDIAC DRUG DEVELOPMENT</b>	
2 The Role of Cardiac Pacemaker Currents in Antiarrhythmic Drug Discovery <i>David A. Saint</i> .....	27
3 Oxygen Free Radicals in Heart Disease: <i>Novel Therapies</i> <i>Elizabeth Roth and Laszlo Hejmel</i> .....	47
4 Mitogen-Activated Protein Kinases-Mediated Signaling in Cardiac Pathology: <i>A Perspective of Novel Therapeutic Targets?</i> <i>Tanya Ravingerova, Miroslav Barancik, and Monika Strniskova</i> .....	67
5 Development of Anti-Inflammatory Drugs for Cardiovascular Disease <i>Melanie B. Smith and David J. Lefer</i> .....	87
6 Development and Use of Platelet Glycoprotein Antagonists in Heart Disease <i>Joel S. Bennett</i> .....	107
7 The Sodium–Hydrogen Exchange System in the Heart: <i>A Target for the Protection of the Ischemic and Reperfused Heart</i> <i>and Inhibition of Heart Failure</i> <i>Morris Karmazyn</i> .....	123
8 Nitric Oxide and Cardiac Ischemia <i>Mariarosaria Bucci, Inmaculada Posadas Mayo,</i> <i>and Giuseppe Cirino</i> .....	141
<b>III FUNCTIONAL ENDPOINTS EVALUATING CARDIAC DRUG ACTIVITY</b>	
9 Ionic Mechanisms of Atrial Fibrillation <i>J. Christian Hesketh and David Fedida</i> .....	163
10 Targeting Ischemic Ventricular Arrhythmias <i>Michael J. A. Walker and Leon J. Guppy</i> .....	175
11 Biochemical Mediators of Ventricular Arrhythmias in Ischemic Heart Disease <i>Hugh Clements-Jewery and Michael J. Curtis</i> .....	203

12	Heterologous Expression Systems and Screening Technologies in Ion Channel Drug Discovery <i>Maurizio Taglialatela</i> .....	227
13	Molecular Diversity of Ion Channels in the Mouse Heart: <i>A Suitable Model for Cardiac Drug Development?</i> <i>Jeanne M. Nerbonne</i> .....	245
14	Delayed Protection of the Myocardium: <i>A Novel Therapeutic Window for Cardiac Drug Development</i> <i>László Szekeres and James Parratt</i> .....	271
 <b>IV CLINICAL ASPECTS IN CARDIAC DRUG DEVELOPMENT</b>		
15	Cardiac Troponin Testing for Detection of Myocardial Infarction: <i>Clinical Utility and Analytical Issues</i> <i>Fred S. Apple</i> .....	297
16	A Genetic Basis for Cardiac Arrhythmias: <i>Current Status and the Future</i> <i>Jeffrey A. Towbin, Matteo Vatta, Hua Li, and Neil E. Bowles</i> .....	317
17	Myocardial Adenoviral Vector Delivery for Cardiovascular Gene Therapy <i>Hendrik T. Tevæearai, Andrea D. Eckhart, and Walter J. Koch</i> .....	351
18	The Role of Pharmacometrics in Cardiovascular Drug Development <i>Paul J. Williams, Amit Desai, and Ene Ette</i> .....	365
19	Gender Differences in Heart Failure: <i>Concerns for Drug Development</i> <i>Mark A. Sussman</i> .....	389
20	Angiogenesis Therapies for Coronary Artery Disease: <i>Trials and Tribulations</i> <i>Michael Simons</i> .....	407
	<i>Index</i> .....	421



<http://www.springer.com/978-1-58829-097-7>

Cardiac Drug Development Guide

Pugsley, M.K. (Ed.)

2003, X, 431 p., Hardcover

ISBN: 978-1-58829-097-7

A product of Humana Press